Expert Interview
A Second Opinion: Discussing the National Institute of Health's Phase III study results of Xolair (omalizumab) for children and adults with food allergies
Ticker(s): RHHBYInstitution: University of Texas
- Pediatric allergist and serves on the faculty at Texas A&M Health Science Center in Round Rock and at the Dell Medical School at the University of Texas at Austin.
- Currently manages approx 2,000-3,000 pediatric patients with food allergies.
- Familiar with the National Institutes of Health Phase III study results of Xolair (omalizumab) for children and adults with food allergies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
